A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation.

Faessel, Hélène M; Obach, R Scott; Rollema, Hans; Ravva, Patanjali; Williams, Kathryn E; Burstein, Aaron H

Faessel, Hélène M; Obach, R Scott; Rollema, Hans; Ravva, Patanjali; Williams, Kathryn E; Burstein, Aaron H.

Affiliation

Faessel HM; Clinical Pharmacology, Primary Care Unit, Pfizer Inc., New London, Connecticut 06320, USA. helene.m.faessel@pfizer.com

Clin Pharmacokinet ; 49(12): 799-816, 2010 Dec.

Article in En | MEDLINE | ID: mdl-21053991

Subject(s)

Benzazepines/pharmacology; Nicotinic Agonists/pharmacology; Quinoxalines/pharmacology; Smoking Cessation/methods; Adolescent; Adult; Age Factors; Aged; Animals; Benzazepines/adverse effects; Benzazepines/pharmacokinetics; Biological Availability; Drug Interactions; Half-Life; Humans; Middle Aged; Nicotinic Agonists/adverse effects; Nicotinic Agonists/pharmacokinetics; Quinoxalines/adverse effects; Quinoxalines/pharmacokinetics; Varenicline; Young Adult

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Quinoxalines / Benzazepines / Smoking Cessation / Nicotinic Agonists Type of study: Prognostic_studies Limits: Adolescent / Adult / Aged / Animals / Humans / Middle aged Language: En Journal: Clin Pharmacokinet Year: 2010 Type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google